Ketamine for Multiple Sclerosis Fatigue

Phase 2 Active not recruiting 110 enrolled Johns Hopkins University United States Department of Defense · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The proposed study is a single-center, phase II, randomized, double-blind, parallel-group, active-placebo-controlled trial of intravenous low-dose ketamine in patients with MS fatigue.

Timeline

Start: 2023-01-01
Primary completion: 2026-05-21
Completion: 2026-10-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ketamine	Small molecule	0.5 mg/kg	Intravenous
Subject	Midazolam	Small molecule	0.05 mg/kg	—

Ketamine for Multiple Sclerosis Fatigue

Summary

Timeline

Drugs

Indications